These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36374330)

  • 1. Immunoprophylactic properties of the Corynebacterium pseudotuberculosis-derived MBP:PLD:CP40 fusion protein.
    Barral TD; Kalil MA; Mariutti RB; Arni RK; Gismene C; Sousa FS; Collares T; Seixas FK; Borsuk S; Estrela-Lima A; Azevedo V; Meyer R; Portela RW
    Appl Microbiol Biotechnol; 2022 Dec; 106(24):8035-8051. PubMed ID: 36374330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corynebacterium pseudotuberculosis cp09 mutant and cp40 recombinant protein partially protect mice against caseous lymphadenitis.
    Silva JW; Droppa-Almeida D; Borsuk S; Azevedo V; Portela RW; Miyoshi A; Rocha FS; Dorella FA; Vivas WL; Padilha FF; Hernández-Macedo ML; Lima-Verde IB
    BMC Vet Res; 2014 Dec; 10():965. PubMed ID: 25527190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioinformatic Approach of B and T Cell Epitopes of PLD and CP40 Proteins of
    Rodríguez-Domínguez MC; Montes-de-Oca-Jiménez R; Vázquez-Chagoyán JC; Rivadeneira-Barreiro PE; Zambrano-Rodríguez PC; Ruiz-Riva-Palacio ME; Gutiérrez-Castillo ADC; de-Castro-Soares S; Vieyra-Reyes P; Arteaga-Troncoso G
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Corynebacterium pseudotuberculosis recombinant proteins rCP09720 or rCP01850 with rPLD as immunogens in caseous lymphadenitis immunoprophylaxis.
    Silva MTO; Bezerra FSB; de Pinho RB; Begnini KR; Seixas FK; Collares T; Portela RD; Azevedo V; Dellagostin O; Borsuk S
    Vaccine; 2018 Jan; 36(1):74-83. PubMed ID: 29174312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NanH and PknG putative virulence factors as a recombinant subunit immunogen against Corynebacterium pseudotuberculosis infection in mice.
    Thais de Oliveira Silva M; Barros de Pinho R; da Rocha Fonseca B; Silvestre Brilhante Bezerra F; Severo Sabedra Sousa F; Kommling Seixas F; Collares T; José Meyer Nascimento R; Wagner Portela R; Ariston Carvalho Azevedo V; Borsuk S
    Vaccine; 2020 Dec; 38(51):8099-8106. PubMed ID: 33190945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide vaccines designed with the aid of immunoinformatic against Caseous Lymphadenitis promotes humoral and cellular response induction in mice.
    Droppa-Almeida D; da Silva GA; Gaspar LMDAC; Pereyra BBS; Nascimento RJM; Borsuk S; Franceschi E; Padilha FF
    PLoS One; 2021; 16(11):e0256864. PubMed ID: 34843474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel approach for an immunogen against Corynebacterium pseudotuberculosis infection: An Escherichia coli bacterin expressing phospholipase D.
    Barros de Pinho R; de Oliveira Silva MT; Brenner G; Dié Alves MS; Azevedo V; Dias Portela R; Borsuk S
    Microb Pathog; 2021 Feb; 151():104746. PubMed ID: 33485993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant CP40 from Corynebacterium pseudotuberculosis confers protection in mice after challenge with a virulent strain.
    Droppa-Almeida D; Vivas WL; Silva KK; Rezende AF; Simionatto S; Meyer R; Lima-Verde IB; Delagostin O; Borsuk S; Padilha FF
    Vaccine; 2016 Feb; 34(8):1091-6. PubMed ID: 26796140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Saponin-adjuvanted recombinant vaccines containing rCP00660, rCP09720 or rCP01850 proteins against Corynebacterium pseudotuberculosis infection in mice.
    Bezerra FSB; Silva MTO; Rezende AFS; Lopes AS; de Pinho RB; Seixas FK; Collares TV; Portela RWD; Azevedo VAC; Borsuk S
    Vaccine; 2021 Apr; 39(18):2568-2574. PubMed ID: 33814234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of Brazilian red propolis and recombinant protein rCP01850 in the immunoprophylaxis of Corynebacterium pseudotuberculosis infection in mice.
    Brilhante Bezerra FS; Silva Rezende AF; Oliveira Silva MT; Sena-Lopes Â; Roesch-Ely M; Pêgas Henriques JA; Padilha FF; Carvalho Azevedo VA; Dias Portela RW; Seixas FK; Collares TV; Savegnago L; Borsuk S
    Microb Pathog; 2020 Dec; 149():104354. PubMed ID: 32569789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycobacterium bovis BCG expressing the proteins CP40 or CP09720 of Corynebacterium pseudotuberculosis promotes protection in mice after challenge.
    de Pinho RB; Barbosa TN; Dall'Agno L; da Rocha Fonseca B; Bezerra FSB; Sousa FSS; Seixas FK; Collares T; Borsuk S
    Vaccine; 2024 Jan; 42(1):33-39. PubMed ID: 38044246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant M. bovis BCG expressing the PLD protein promotes survival in mice challenged with a C. pseudotuberculosis virulent strain.
    Leal KS; de Oliveira Silva MT; de Fátima Silva Rezende A; Bezerra FSB; Begnini K; Seixas F; Collares T; Dellagostin O; Portela RW; de Carvalho Azevedo VA; Borsuk S
    Vaccine; 2018 Jun; 36(25):3578-3583. PubMed ID: 29759378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant esterase from Corynebacterium pseudotuberculosis in DNA and subunit recombinant vaccines partially protects mice against challenge.
    Brum AA; Rezende AFS; Brilhante FS; Collares T; Begnine K; Seixas FK; Collares TV; Dellagostin OA; Azevedo V; Santos A; Portela RW; Borsuk S
    J Med Microbiol; 2017 May; 66(5):635-642. PubMed ID: 28516859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caseous lymphadenitis vaccine development: site-specific inactivation of the Corynebacterium pseudotuberculosis phospholipase D gene.
    Tachedjian M; Krywult J; Moore RJ; Hodgson AL
    Vaccine; 1995 Dec; 13(18):1785-92. PubMed ID: 8701594
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Droppa-Almeida D; Ferreira CS; Brito I; Borsuk S; Rodríguez JAL; Lima-Verde IB; Padilha FF
    Vet Med Int; 2021; 2021():9931731. PubMed ID: 34373777
    [No Abstract]   [Full Text] [Related]  

  • 16. Protection of sheep against caseous lymphadenitis by use of a single oral dose of live recombinant Corynebacterium pseudotuberculosis.
    Hodgson AL; Tachedjian M; Corner LA; Radford AJ
    Infect Immun; 1994 Dec; 62(12):5275-80. PubMed ID: 7960105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Putative virulence factors of Corynebacterium pseudotuberculosis FRC41: vaccine potential and protein expression.
    Santana-Jorge KT; Santos TM; Tartaglia NR; Aguiar EL; Souza RF; Mariutti RB; Eberle RJ; Arni RK; Portela RW; Meyer R; Azevedo V
    Microb Cell Fact; 2016 May; 15():83. PubMed ID: 27184574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of
    Silva MTO; Bezerra FSB; de Pinho RB; de Santana Ferreira C; Vivas WL; Portela RWD; Azevedo VAC; Borsuk S
    J Med Microbiol; 2019 Dec; 68(12):1759-1765. PubMed ID: 31724936
    [No Abstract]   [Full Text] [Related]  

  • 19. Vaccination against
    Moussa IM; Ali MS; Hessain AM; Kabli SA; Hemeg HA; Selim SA
    Saudi J Biol Sci; 2016 Nov; 23(6):718-723. PubMed ID: 27872567
    [No Abstract]   [Full Text] [Related]  

  • 20. CP40 from Corynebacterium pseudotuberculosis is an endo-β-N-acetylglucosaminidase.
    Shadnezhad A; Naegeli A; Collin M
    BMC Microbiol; 2016 Nov; 16(1):261. PubMed ID: 27821068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.